To test the relevance of these findings to human disease, we first generated two BC CML PDX models with high human leukemic cell burden (both: >50%) by transplanting CD34+ cells from a few BC CML patients into NSG-SGM3 (NSGS) mice. This evidence concerns the gene CD34 and breast cancer.